Latest Development Funding News

Opthea Limited reported a 26% reduction in net loss for FY2025 despite discontinuing its wet AMD drug after failed Phase III trials. The company settled its Development Funding Agreement with investors, securing liquidity and planning a strategic pivot.

Streamplay Studio’s FY25 preliminary results reveal a striking 121% income surge, driven by the strategic acquisition of North American game studio Noodlecake, positioning the company for a $10 million annual income trajectory.

Streamplay Studio Limited reported a remarkable 201% surge in operating revenue for FY25, driven by its strategic acquisition of Noodlecake Studios and expansion into new markets. Despite a wider operating loss, the company achieved positive cash flow and profitability in the final quarter, signaling a promising turnaround.

MEC Resources Ltd has reported a net profit of $207,490 for the 2025 financial year, reversing prior losses, while advancing a significant legal challenge through its investee Advent Energy Ltd and raising $2.6 million via an entitlement offer.

Control Bionics Limited reported a 14.8% revenue increase to $6.14 million for FY2025 but also a 3.3% rise in net loss to $6.11 million, while pursuing a $2 million rights issue and expanding its investment portfolio.

Kalina Power Limited reported a net loss of AUD 4.67 million for FY25 with no revenue generated, while pursuing strategic asset sales and capital raising amid going concern uncertainties.

Godolphin Resources is raising $3.03 million through a placement and entitlement offer to fast-track exploration and development at its Lewis Ponds Project in NSW, following a significant resource upgrade.

Starpharma has received a $3.7 million R&D Tax Incentive refund for the 2025 financial year, reinforcing its commitment to advancing dendrimer technology and biotechnology innovation in Australia.

Control Bionics Limited has announced a $2.06 million non-renounceable rights issue to fund the commercial expansion of its NeuroStrip device and bolster NeuroNode operations. The capital raise is underwritten to approximately $1.15 million by major shareholders and strategic partners.

Pure Foods Tasmania has secured a $400,000 investment from entrepreneurs Jon Kontopos and Matthew Abrahams as part of a broader $750,000 capital raising effort, reinforcing confidence in the company’s turnaround plan ahead of its upcoming shareholder vote.

Opthea Limited has terminated its sozinibercept wet AMD program following Phase 3 trial failures and settled a major funding agreement, setting the stage for a strategic reset.

Opthea has successfully settled its Development Funding Agreement, avoiding a potential $680 million liability and securing $20 million in cash. Leadership changes include the CEO and CFO stepping down, with the Chairman assuming CEO duties.